Q3 FY2026 · ended Jun 30, 2026 · Revenue $1.49M, -10.4% YoY · Filed Aug 14, 2026
Citius Oncology, Inc. (CTOR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.5 million and a net loss of $8.9 million. As of Jun 30, 2026 it held $16.6 million in cash and investments and $6.4 million in total debt.
Revenue
$1.49M
-10.4% vs prior quarter
Net income
$-8.92M
-66.2% vs year-ago quarter
Operating cash flow
$-2.71M
+29.3% vs prior quarter
Free cash flow
—
EPS
$-0.08
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
92.98M
+18.6% vs year-ago quarter
Net cash
$10.15M
Q3 FY2026
Operating margin
-583.5%
Q3 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTOR (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Cranford, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1851484
- Former names
- TenX Keane Acquisition (until Aug 5, 2024)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | — | — |
| Operating income | -$8.7M | -$28.6M | -$5.3M | -$4.7M | -$4.9M |
| Net income | -$8.9M | -$26.6M | -$5.5M | -$5.0M | -$5.4M |
| Diluted EPS | -$0.08 | -$0.27 | -$0.06 | -$0.06 | -$0.08 |
| Operating cash flow | -$2.7M | -$3.8M | -$7.4M | — | — |
| Total assets | $112.1M | $100.7M | $110.0M | $100.9M | $91.7M |
| Total liabilities | $71.7M | $65.4M | $51.6M | $56.1M | $59.3M |
| Stockholders' equity | $40.4M | $35.3M | $58.4M | $44.9M | $32.4M |
| Cash and investments | $16.6M | $2.6M | $7.3M | — | $112 |
| Total debt | $6.4M | — | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 29, 2026 | Sep 29, 2026 |
| ARS | Annual report to shareholders | Aug 26, 2026 | Sep 30, 2025 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 268 Citius Oncology, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.